Steve. you, Thank great. Okay,
the As care our and we and under continue our operate ours our has a the employees, been providers, COVID-XX to patients partners. pandemic, primary health of safety of concern
we've March. work a from As home instituted staff. our effect It such for in to continues in policy office remain
functioning. research our is However, laboratory open and
for Fortunately continuing teleconferences platforms operation our us, of partners effective in have online keyword by research remain to meeting development our and to programs. and we using various been most in continue advance in
this to for there will activity which we can prepared virus, on activities based outcome. be we of currently country. understand However, be is happening disruptions the And resurgence business with potential the resumption further across
July AMAG As Vyleesi XXXX, in Steve acquired from we mentioned Pharmaceuticals.
Vyleesi Just value potential of the and and as operational on strategic on a divestiture AMAG of reminder, based not at Vyleesi. was AMAG changes
details of Although a access commercial rapidly these very the to led of we a had directions, are late and Vyleesi has I the and to This some nominal sub-optimal plan, July, Steve economics. covered accomplishments addressed Steve’s Vyleesi. of that experience efforts patient focus on marketing emphasize. would in an Under have we assembled commercial unfavorable the and and limited that team number has there patient issues. of [re-acquired] excellent there distribution like been When motivated
Over the specialty improved solidified we expanded and the insurance last distribution quarter, the our experience Vyleesi pharmacies, patient by coverage. have we network, have retraining
a potential improved us believe geo-targeting for economics are premenopausal desire and the ensuring offices [re-licensing] and women a partner to manner, a ultimate treatment our put of sexual financial we Vyleesi to foundation of availability investment. much effective These mentioned, activities continued option a are begin, Vyleesi and Steve a or engaging done committed obtain cost to of a the selective a have prescribers, on a providers have with objective with for demonstrate campaign. leading us Vyleesi position in disorder to pace hypoactive accomplishments These the and with return as value experience, have HSDD in patient strong our to better virtual and as laid addition, virtual relationships what marketing been to record healthcare that In is meetings. I improved and
on, energy intake, food a move melanocortin know the sexual which Palatin resolution has function, focus on and of system responses. including many regulation we is balance, scientific you of in inflammatory involved primary As of
successful melanocortin disorder. on function. for melanocortin eventual of first program research resulted by its women sexual with FDA This the as sexual premenopausal role Our Vyleesi based work and the the system first discovery treatment approval of regulating in desire in the on-demand the hypoactive was
inflammation. the system Our ability current that research turn melanocortin drugs the focus is resolve target on developing to down or of
conducted resolution have cells melanocortin have We a system variety results shown the of the as multiple cells of to TNF-alpha, inhibition mediating a cytokines, from in These modulating and interleukin-XX. regulatory us conversion and the potential production pro-resolution have models And pro-inflammatory interleukin-X, include the and drugs processes. the that others, the cytokines as the resolve such that of pro-inflammatory activities preclinical in candidates inflammatory conditions. and demonstrated such drug developed upregulation by others of research anti-inflammatory state, immune with immune targeting to of of inflammatory
plays diseases. have reducing addition, the we a as broad The role occurs of inflammatory treating utility in In that inflammatory drugs fibrotic Therefore, believe will part patients. that for inflammatory long-term diseases. health many system response the melanocortin negative fibrosis of the disease from consequences melanocortin in has resulting
[ocular] dry have eye other clinical as for We and developed uveitis diseases drug stage retinal indications such non-infectious disease disease, candidates diseases. ocular
We such diseases cabinet as ulcerative also colitis. have a gastrointestinal clinical stage for drug
locally, pain, that disease fully an validated redness, XX-week this dry XXXX. experience treatment endpoints began which the dry data that disease. study drop objective The we is required January examples period. X dry randomized disease varied, [zero aspects a measured in and a the will co-primary ophthalmic for eye in strategy. enrolled Phase would eyes. sicca many a divided resulting December receptor with to with XXX primary data eye into is symptoms. in the tear study later Phase and eye is and inflammation of using direct agonists are affects PL-XXXX vision. and staining to system of of disease Causes before A melanocortin dry trial melanocortin eye provide signs production. blurry patients and aspects known which disease study of PL-XXXX is by eye vision In and and X PL-XXXX The negative eye solution in patients believe trials two was the eye multicenter to irritation, disease sign study sign of the formulation by is on Symptoms the as a Dry lesions advance corneal with into disease, XXXX. start discomfort inferior are that are XXXX. the of placebo we fluorescein studies July half clinical clinical XXXX, the cornea Our study which PL-XXXX I are year-end, first reduce of track the also evidence Endpoints to stage review underlies data categories corneal dry are symptom PL-XXXX of design scale]. and keratoconjunctivitis eye of conjunctiva activating of regulatory in and our ocular a would are like comparing a disease. itchy coming is are control With in Examples blurry
eye multiple on is endpoints. use also have of X with a in that disease. secondary included We only single secondary to effects typical It Phase a signs endpoint endpoints primary study and symptoms PL-XXXX dry multiple measure
required study significant. be FDA, current co-primary multiple analysis. advances] after primary we one of used sub-populations endpoints statistically statistical endpoint significance are potentially the use or with with both or the co-primary potential study signs two in outcomes studies, endpoints strategy part secondary designed endpoints that as for the of symptoms are Phase both X support the outcomes that so or one chose if pivotal the that the of However, to discussions or other X the We've of include Phase could [the These the PLXXXX. co-primary specific
and and profile two X substantial Phase studies. treatment over PL-XXXX Following market. X We and possibility may for one as opportunity efficacy annual commercial represents of growth substantial dry believe sales market eye demographics. Phase dry a disease risk billion eye allows the The the based that for on the Phase will be potential of study safety $X tolerability X the required penetration and continued the allow in of the market strategy used reduces stable patient pivotal
from preclinical a Now anti-inflammatory demonstrated the program. COVID-XX disease and moving due tissue models, activity lung to protect onto particular PL-XXXX has our disease to ability PL-XXXX, fibrosis. in our In damage pulmonary
inflammation we patients progressive for concerning infection with BARDA reduce with a held second treatment infections. quarter with fibrosis potential of potential calendar a discussions disease. patients In the PL-XXXX lung the COVID-XX PL-XXXX may for as in As with treatment associated COVID-XX XXXX,
on of was moved the we the XXXX, requirements of that COVID submitted the a advice concerning discussions PL-XXXX clinical we forward patients. studies. to packaged study FDA PL-XXXX the second pre-IND clinical outcomes progress a potential advice and quarter and the to into this in begin One with the of discussion received In FDA detailed data
These Following clinical IND of required COVID-XX in all we plan, to investigational active PL-XXXX new conducting our such as development, and PL-XXXX file manufacture or studies current protocol placebo COVID-XX of drug trial begin patients. are and include an selection identification, the activities an clinical site application activities doses. CRO, and clinical needed
be not these begin able half we the impacted and that placebo doses. the complete study required activities However, IND the be PLXXXX. Until an ability in completed, the activities delay of PLXXXX manufacturing manufacturing to complete to a acquiring the We and first to to has anticipate will COVID-XX will pandemic able active syringes file to we needed with XXXX. a our not until due manufacture are
in and patients. is rapidly studies discussed in conduct impacts studies previous COVID-XX XX-K. treating and COVID-XX design, the patients in The risk, which As clinical in is release to clinical evolving, press landscape calls, conducting ability our for
COVID-XX and longer unfortunately this we support a of we considered that such earlier clinical support. of PLXXXX we program applying studies, the to only is government's the study to programs external and program the the As government year, that is active of positive applied we in recently subject PLXXXX start programs the review, Phase prioritized risk as and X to clinical operational receiving Earlier funding are conducting and have funding clinical process provide uncertainty but received no a and programs. funding informed support were active the
We continue of external for hopefully to seek support this support and other look program. to finding successful sources forward
based COVID-XX, to to scheduled This Our second scientific fraction. natriuretic understanding evaluated in Phase is in system which to PL-XXXX, research we our system, impact the of patients using finally, half of due work a of and delay the in time slight XXXX. in agonists a additional our receptor The the a supported clinical being collaboration is two drug trial are proof Association heart dosed. is is indication the track for melanocortin enrollment and study the oral colitis ejection Phase of of our the manufacturing expand that clinical retinal disease is and mechanism colon been preserved to the American peptide PLXXXX clinical half activities to with as Updating is and and Heart in centers ulcerative first on with for a Grant. conducted a failure X begin candidate I’m and A ocular peptide naturally this inflammatory major diseases. release happy for other diseases, bowel in going study required by medical academic our remain a has begun report formulation we've has study and treatment be program first And patient the on pre-clinical begin to patient drug XXXX. XA
the have website In management and acted to quickly on operations programs the pandemic, find Addressing took programs. response patients, continue and directors to our pandemic, employees been can able business of health board of You ensure the the our actions information adjust executive and partners. additional to to our we to and our advance on employees, COVID-XX www.palatin.com. safety we our immediate care
allow our to position ability programs our cash in pandemic a emerge will from advance strong position. the and to development Palatin Our continue to healthy
just significant Pharmaceuticals, Our we marketing Vyleesi progress. directions and an that place excellent begun a Steve now team Vyleesi. have put made many we in inherited commercial selective activities is of we AMAG have deficiencies from commercial the have of Wills Under
Korean to with their into advancing and territories. are regulatory those partners, sale of for We our support now Vyleesi submissions and continue to studies approval and clinical in Vyleesi ultimate work Chinese which
clinical to We believe enrollment HSDD completed company. a of treatment with the as a Vyleesi continue increase the program, and our view this to in initiated opportunity value X [Vyleesi] of of Larger a value for women Phase and major as study. we
the forward We December if move data and track are is data in for on preparing positive. to
will operational to continue we to by continue the with pandemic. COVID-XX rest to deal As forward look the XXXX, posed of the we challenges
their advancement. one We pipeline we in are COVID-XX will year, or strong clinical colitis remain and past positioned patients In and clinical to on research have start dedication XXXX. new like our I to the and all their novel in to a partners the the ulcerative the of Vyleesi Based disease their more working indications other to development adjustments environment in team a would thank on for Palatin in candidates and closing, of candidates. rapid activities novel our work continued advancement completed drug we studies commercial focused ocular
We questions. open now will the to call
